Study to check the effect of Saraglitazor vs Dapagliflozin on abnormal fibroscan parameters in patients with Metabolic associated steatosis liver disease at a tertiary care centre

INTERVENTION: Intervention1: Tablet Saroglitazor: 4mg tablet given orally once daily for 24 weeks Control Intervention1: Tablet Dapagliflozin: 10mg orally once daily for 24 weeks CONDITION: Health Condition 1: E888‐ Other specified metabolic disorders PRIMARY OUTCOME: Saroglitazar and dapagliflozin is expected to be associated with improvement in hepatic ; parametersTimepoint: baseline 4 weeks 8 weeks SECONDARY OUTCOME: lipid profile, including triglycerides, total cholesterol, LDL‐C, ; HDL‐C, and non‐HDL cholesterol. ; To assess changes in glycemic parameters such as fasting blood glucose and HbA1c. ; To evaluate changes in anthropometric parameters such as body weight, BMI, and ; waist circumference. ; To assess the change in FIB‐4 Age,AST,ALT,Platelet countTimepoint: baseline,12 weeks,24 weeks INCLUSION CRITERIA: Participants with Abnormal fibro scan parameters and with metabolic dysfunction associated steatosis liver disease